文献速递心力衰竭与心肌病

射血分数降低心衰的加速与个性化治疗

Accelerated and personalized therapy for heart failure with reduced ejection fraction.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究基于六项HFrEF关键试验数据建模,评估加速滴定和优化用药顺序对结局的影响。结果显示,加速滴定可在起始治疗12个月内每1000例患者减少23例心衰住院或心血管死亡复合终点及7例全因死亡;优化顺序进一步减少24例复合终点和6例死亡。最优替代顺序以SGLT2抑制剂和MRA为首两种治疗。

要点

  • 加速滴定可在12个月内每1000例减少23例复合终点和7例死亡。
  • 优化用药顺序可额外减少24例复合终点和6例死亡。
  • 最优顺序以SGLT2抑制剂和MRA为首两种药物。

核心结论

  • 建模提示加速滴定和优化顺序可在起始治疗12个月内每1000例至少预防14例死亡和47例复合终点事件。
  • 标准治疗指导可能无法为HFrEF患者带来最佳结局,但需临床试验验证。

研究设计与样本

  • 基于六项HFrEF关键试验数据的建模研究。

主要发现

  • 快速滴定方案在12个月内每1000例减少23例心衰住院或心血管死亡复合终点和7例全因死亡。
  • 优化替代顺序额外减少24例复合终点和6例死亡。
  • 最优替代顺序包括SGLT2抑制剂和MRA作为前两种治疗。

临床怎么用

  • 可考虑加速滴定HFrEF治疗药物以尽早获益。
  • 可考虑以SGLT2抑制剂和MRA作为起始两种药物优化顺序。

局限性

  • 结果为建模分析,需临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Previously, guidelines recommended initiating therapy in patients with heart failure and reduced ejection fraction (HFrEF) in a sequence that follows the chronological order in which trials were conducted, with cautious up-titration of each treatment. It remains unclear whether this historical approach is optimal and alternative approaches may improve patient outcomes. METHODS AND RESULTS: The potential reductions in events that might result from (i) more rapid up-titration of therapies used in the conventional order (based on the chronology of the trials), and (ii) accelerated up-titration and using treatments in different orders than is conventional were modelled using data from six pivotal trials in HFrEF. Over the first 12 months from starting therapy, using a rapid up-titration schedule led to 23 fewer patients per 1000 patients experiencing the composite of heart failure hospitalization or cardiovascular death and seven fewer deaths from any cause. In addition to accelerating up-titration of treatments, optimized alternative ordering of the drugs used resulted in a further reduction of 24 patients experiencing the composite outcome and six fewer deaths at 12 months. The optimal alternative sequences included sodium-glucose cotransporter 2 inhibition and a mineralocorticoid receptor antagonist as the first two therapies. CONCLUSION: Modelling of accelerated up-titration schedule and optimized ordering of treatment suggested that at least 14 deaths and 47 patients experiencing the composite outcome per 1000 treated might be prevented over the first 12 months after starting therapy. Standard treatment guidance may not lead to the best patient outcomes in HFrEF, though these findings should be tested in clinical trials.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Shen, Jhund, Docherty, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J. 2022. PMID: 35467706. doi:10.1093/eurheartj/ehac210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。